HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

2022H2 China Healthcare Investment Strategy and Top Picks

WuXi AppTec (603259.CH/2359.HK) 2022H1 - The Concerns Behind and the Outlook

Pre-IPO Lepu Medical Technology - Lepu Is in a Difficult Position and Turning It Around Takes Time

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Thematic (Sector/Industry)

Hong kong Healthcare equipment and services / Thematic (Sector/Industry)

<ul>
<li>PCR dominates the hospital market, but as targeted drug prices fall, PCR cannot have high pricing,indicating compressing market space. The whole logic goes from "To C " to "To B”.</li>
<li>NGS has advantages in new demand of individualized diagnosis and treatment of difficult diseases and drug efficacy prediction in response to complex mechanisms. It will seize market share from PCR.</li>
<li>A “good story” for related companies should not just focus on PCR (current fundamental), but NGS (long term potential) and may also cover early screening products (multidimensional growth).  </li>
</ul>


PCR dominates the hospital market, but as targeted drug prices fall, PCR cannot have high pricing,indicating compressing market space. The whole logic goes from "To C " to "To B”.
NGS has advantages in new demand of individualized diagnosis and treatment of difficult diseases and drug efficacy prediction in response to complex mechanisms. It will seize market share from PCR.
A “good story” for related companies should not just focus on PCR (current fundamental), but NGS (long term potential) and may also cover early screening products (multidimensional growth).  


Industry Report - Insights on China Companion Diagnostics Market (Business Logic and Outlook)